Developer docs
API playgroundTry for free, no card

Search company profiles

Argo Biopharma

Full company profile

uuid0000w89

Namestring
Argo Biopharma
Legal namestring
Argo Biopharma Research Corporation
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Argo Biopharma is a clinical-stage biotechnology company founded in 2021 and headquartered in Shanghai (Jiading district, with corporate operations in Pudong New Area), with a regional office in New York supporting international business development. The company is dedicated to developing next-generation siRNA (small interfering RNA) therapeutics and is built around its proprietary RADS platform (RNA molecules with superior Activity, Durability, and Safety), which combines chemical modification, sequence design, and extrahepatic delivery capabilities. Argo's stated design goal is 'one injection per year' dosing for certain indications. The company currently has seven RNAi candidates in clinical development and a broader pipeline of more than 20 therapeutic programs spanning cardiovascular disease, hereditary angioedema, chronic hepatitis B, complement-mediated diseases (paroxysmal nocturnal hemoglobinuria, IgA nephropathy), transthyretin amyloidosis, hypertension, metabolic disorders, and neurodegenerative conditions.

Argo's commercial model is licensing- and collaboration-driven rather than product-sales-driven. The company has executed two landmark multi-asset collaborations with Novartis — a January 2024 deal valued at $185 million upfront plus up to $4.165 billion in potential milestones and tiered royalties, and a September 2025 expansion delivering $160 million upfront plus up to $5.2 billion in potential value — covering cardiovascular siRNA programs (BW-20829/Lp(a), BW-00163/hypertension, BW-00112/ANGPTL3, plus discovery-stage molecules). Argo retains rights in Greater China for most programs and advances several wholly-owned assets independently, including BW-20805 (HAE, FDA Fast Track), BW-20507 (chronic hepatitis B, NMPA Breakthrough Therapy Designation), BW-40202 (complement), BW-50218 (ATTR), and BW-01 (severe hypertriglyceridemia). Equity funding has come from Apricot Capital (angel), Loyal Valley Capital (Series A lead), CS Capital (Series A+ lead), and a syndicate of Chinese growth investors, totaling approximately $108 million across three pre-2024 rounds.

The company is led by co-founders Dr. Dongxu Shu (CEO, ex-Arrowhead Pharmaceuticals) and Dr. Patrick Shao (CSO, ex-Arrowhead/Merck), with Dr. James Jin (CMO, previously Head of Clinical Development at Novartis China where he led the Asia Phase 3 of LEQVIO/inclisiran), Patrick Gallagher (CBO/Head of US, ex-Pfizer/AbbVie/Flagship), and — as of March 2026 — Dr. Gena Wang (CFO/CSO, ex-Barclays top-3 ranked biotech analyst) rounding out the executive team. Argo was named to Fast Company's 2026 list of the World's Most Innovative Companies, reflecting external validation of its RADS platform and pipeline productivity.

Short descriptiontext

Argo Biopharma is a clinical-stage Chinese biotechnology company developing next-generation siRNA therapeutics through its proprietary RADS platform, targeting cardiovascular, rare, viral, and metabolic diseases for global out-licensing, primarily to Novartis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersShanghai, China
HQ citystring
Shanghai
HQ countrystring
China
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
siRNA therapeutics, RNAi drug development, cardiovascular disease treatment, chronic hepatitis B therapy, hereditary angioedema drug
Industry1 code
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Services-Commercial Physical & Biological Research8731
Product category
RNAi Therapeutics / siRNA Drug Development
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Argo Biopharma generates revenue through licensing deals with pharmaceutical companies. The company receives upfront payments, milestone payments tied to clinical and regulatory achievements, and tiered royalties on commercial sales.

argobiopharma.com
2Strategic Collaborations
TypeLicensing Royalties
Description

Multi-program RNAi licenses and strategic collaborations with Novartis generating upfront payments of $185 million in January 2024 and $160 million in September 2025, with total potential deal values exceeding $4 billion and $5 billion respectively.

biospace.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Argo Biopharma is a clinical-stage biotechnology company that develops next-generation siRNA (small interfering RNA) therapeutics using its proprietary RADS platform (RNA molecules with superior Activity, Durability, and Safety). The company advances a pipeline of RNAi drug candidates targeting cardiovascular diseases, rare diseases, viral infections (HBV), complement-mediated diseases, and metabolic conditions, and monetizes these candidates through licensing and strategic collaboration agreements with global pharmaceutical companies such as Novartis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • BW-20805 achieved 99% reduction in time-normalized HAE attack rate with 83% of participants attack-free at 600mg Q24W dose
+4 more records
Product overview1 text field

Argo Biopharma is a clinical-stage biotechnology company developing next-generation siRNA (small interfering RNA) therapeutics powered by its proprietary RADS platform. The company has a robust pipeline of multiple siRNA drug candidates targeting cardiovascular diseases (BW-01, BW-20829), rare diseases (BW-20805 for HAE), viral infections (BW-20507 for HBV), complement-mediated diseases (BW-40202 for PNH/IgAN), metabolic conditions, and specialty diseases. The company collaborates strategically with Novartis for several cardiovascular programs (BW-00163, BW-20829) and advances multiple candidates independently. Currently, seven RNAi candidates are in clinical development.

Product and service8 records
1RADS siRNA Platform
CategoryProprietary Technology Platform / siRNA Drug Discovery
Description

Proprietary siRNA drug discovery and development platform (RNA molecules with superior Activity, Durability, and Safety) used by Argo Biopharma to design, modify, and deliver next-generation RNAi therapeutics targeting a broad range of indications including cardiovascular diseases, rare diseases, viral infections, metabolic conditions, and CNS disorders. The platform supports sequence design, chemical modification, hepatic and extrahepatic delivery, and is engineered for long-acting dosing profiles.

2BW-01
CategoryClinical-stage siRNA Candidate / Cardiovascular & Metabolic
Description

SiRNA therapeutic candidate for severe hypertriglyceridemia and cardiovascular disease, developed from the RADS platform; the first independently developed siRNA drug by Argo Biopharma.

3BW-20805 (PKK)
CategoryClinical-stage siRNA Candidate / Rare Disease (HAE)
Description

SiRNA therapeutic targeting prekallikrein (PKK) for the prophylactic treatment of hereditary angioedema (HAE); demonstrated 99% reduction in time-normalized HAE attack rate with 83% of participants attack-free at 600mg Q24W dose and over 90% plasma PKK reduction across all treatment groups.

4BW-20507
CategoryClinical-stage siRNA Candidate / Viral Hepatitis (HBV)
Description

SiRNA molecule targeting HBV messenger RNA for the treatment of chronic hepatitis B (CHB); received Breakthrough Therapy Designation from China CDE of NMPA based on potent antiviral activity and favorable safety profile in early-stage clinical trials.

5BW-40202 (CFB)
CategoryClinical-stage siRNA Candidate / Complement-mediated Diseases
Description

SiRNA therapeutic targeting complement factor B (CFB) mRNA in the liver for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN).

6BW-50218
CategoryClinical-stage siRNA Candidate / Rare Disease (ATTR Amyloidosis)
Description

SiRNA therapeutic targeting transthyretin protein (TTR) for the potential treatment of ATTR amyloidosis and other TTR-related diseases, developed from the RADS platform with hepatic delivery.

7BW-20829 (DII235)
CategoryClinical-stage siRNA Candidate / Cardiovascular (Lp(a))
Description

SiRNA therapeutic targeting elevated Lipoprotein(a) in patients with atherosclerotic cardiovascular disease; licensed to Novartis and progressed to Phase 2b under the exclusive collaboration agreement.

8BW-00163 (QCZ484)
CategoryClinical-stage siRNA Candidate / Cardiovascular (Hypertension)
Description

SiRNA therapeutic for hypertension developed from the RADS platform; part of the exclusive license and collaboration agreement with Novartis (the fourth RADS platform asset to enter mid-stage clinical development).

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2025-09-03
Description

Expanded multi-asset collaboration with Novartis for cardiovascular disease programs. Novartis received option to license ex-China rights to two discovery-stage molecules for severe hypertriglyceridemia and mixed dyslipidemia, plus right of first negotiation for BW-00112 (ANGPTL3) in Phase II. Deal includes $160 million upfront, potential milestones up to $5.2 billion, and tiered royalties. This builds on the January 2024 partnership valued at $4.165 billion total potential.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-01-07
Description

Landmark multi-program RNAi licensing and strategic collaboration with Novartis. Argo granted Novartis exclusive global license for Phase 1 cardiovascular program, exclusive ex-Greater China license for Phase 1/2a cardiovascular program, and option to license compounds directed against up to two additional cardiovascular targets. Novartis paid $185 million upfront with total potential deal value up to $4.165 billion plus tiered royalties.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Market-leading siRNA therapeutics company with multiple approved products (Givlaari, Oxlumo, Leqvio, Amvuttra). Directly comparable to Argo as a clinical/commercial-stage siRNA developer targeting similar cardiovascular, rare disease, and metabolic indications with GalNAc-conjugated RNAi platform.

TypeDirect peer
Description

Clinical-stage siRNA company with the TRiM platform targeting liver and extrahepatic tissues. Several Argo founders (CEO Dongxu Shu, CSO Patrick Shao) were previously at Arrowhead, making it the most direct platform and people-comparable peer.

TypeDirect peer
Description

UK-based clinical-stage siRNA company developing GalNAc-conjugated RNAi therapeutics for cardiovascular and rare diseases. Direct platform and indication overlap, including Lp(a) and cardiovascular programs that compete with Argo's BW-20829 and BW-00163.

TypeDirect peer
Description

Acquired by Novo Nordisk in 2021 for its GalXC RNAi platform. Direct platform peer historically; under Novo Nordisk, continues to compete in cardiometabolic RNAi — relevant comparable for what a major-pharma-acquired siRNA platform looks like at scale.

TypeBroad incumbent
Description

Established antisense oligonucleotide (ASO) therapeutics company with multiple approved products (Spinraza, Tegsedi, Waylivra). Competes in adjacent RNA-targeting modality for similar indications including cardiovascular and rare disease; relevant for platform validation and partnering models.

TypeEmerging player
Description

Clinical-stage RNA therapeutics company using PRISM platform for stereopure oligonucleotides. Comparable as a smaller-cap RNA platform targeting neurological and rare diseases with differentiated chemistry — relevant peer for Argo's extrahepatic delivery ambitions.

TypeEmerging player
Description

Clinical-stage infectious disease company with siRNA-based hepatitis B program (VIR-2218). Directly comparable to Argo's BW-20507 for chronic hepatitis B as the leading competing RNAi approach to functional cure.

TypeBroad incumbent
Description

Global pharmaceutical leader with significant RNAi investment through Dicerna acquisition and independent cardiovascular/metabolic programs. Comparable as the type of deep-pocketed incumbent that could be a future acquirer or strategic partner for Argo-style siRNA platforms.

TypeOthers
Description

Argo's flagship strategic partner with multiple licensed siRNA programs and >$9B in potential deal value. Relevant as the incumbent that has validated Argo's platform and that any future investor would benchmark against for ongoing partnership economics.

TypeRegional player
Description

China-based clinical-stage siRNA therapeutics company developing cardiovascular and rare disease RNAi drugs. Closest geographic/direct competitor in the China siRNA ecosystem, with overlapping cardiovascular and HAE programs.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Argo Biopharma

RNAi Therapeutics / siRNA Drug Developmentargobiopharma.com

Argo Biopharma is a clinical-stage Chinese biotechnology company developing next-generation siRNA therapeutics through its proprietary RADS platform, targeting cardiovascular, rare, viral, and metabolic diseases for global out-licensing, primarily to Novartis.

What Argo Biopharma does

Argo Biopharma is a clinical-stage biotechnology company founded in 2021 and headquartered in Shanghai (Jiading district, with corporate operations in Pudong New Area), with a regional office in New York supporting international business development. The company is dedicated to developing next-generation siRNA (small interfering RNA) therapeutics and is built around its proprietary RADS platform (RNA molecules with superior Activity, Durability, and Safety), which combines chemical modification, sequence design, and extrahepatic delivery capabilities. Argo's stated design goal is 'one injection per year' dosing for certain indications. The company currently has seven RNAi candidates in clinical development and a broader pipeline of more than 20 therapeutic programs spanning cardiovascular disease, hereditary angioedema, chronic hepatitis B, complement-mediated diseases (paroxysmal nocturnal hemoglobinuria, IgA nephropathy), transthyretin amyloidosis, hypertension, metabolic disorders, and neurodegenerative conditions.

Argo's commercial model is licensing- and collaboration-driven rather than product-sales-driven. The company has executed two landmark multi-asset collaborations with Novartis — a January 2024 deal valued at $185 million upfront plus up to $4.165 billion in potential milestones and tiered royalties, and a September 2025 expansion delivering $160 million upfront plus up to $5.2 billion in potential value — covering cardiovascular siRNA programs (BW-20829/Lp(a), BW-00163/hypertension, BW-00112/ANGPTL3, plus discovery-stage molecules). Argo retains rights in Greater China for most programs and advances several wholly-owned assets independently, including BW-20805 (HAE, FDA Fast Track), BW-20507 (chronic hepatitis B, NMPA Breakthrough Therapy Designation), BW-40202 (complement), BW-50218 (ATTR), and BW-01 (severe hypertriglyceridemia). Equity funding has come from Apricot Capital (angel), Loyal Valley Capital (Series A lead), CS Capital (Series A+ lead), and a syndicate of Chinese growth investors, totaling approximately $108 million across three pre-2024 rounds.

The company is led by co-founders Dr. Dongxu Shu (CEO, ex-Arrowhead Pharmaceuticals) and Dr. Patrick Shao (CSO, ex-Arrowhead/Merck), with Dr. James Jin (CMO, previously Head of Clinical Development at Novartis China where he led the Asia Phase 3 of LEQVIO/inclisiran), Patrick Gallagher (CBO/Head of US, ex-Pfizer/AbbVie/Flagship), and — as of March 2026 — Dr. Gena Wang (CFO/CSO, ex-Barclays top-3 ranked biotech analyst) rounding out the executive team. Argo was named to Fast Company's 2026 list of the World's Most Innovative Companies, reflecting external validation of its RADS platform and pipeline productivity.

Argo Biopharma firmographics

Firmographics
Name
Argo Biopharma
Legal name
Argo Biopharma Research Corporation
Website
https://argobiopharma.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
11–50 employees
Short description
Argo Biopharma is a clinical-stage Chinese biotechnology company developing next-generation siRNA therapeutics through its proprietary RADS platform, targeting cardiovascular, rare, viral, and metabolic diseases for global out-licensing, primarily to Novartis.
Ownership category
akta.pro rank

Argo Biopharma industry classification

Industry
Product category
RNAi Therapeutics / siRNA Drug Development
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • SiRNA therapeutics
  • RNAi drug development
  • Cardiovascular disease treatment
  • Chronic hepatitis B therapy
  • Hereditary angioedema drug

Where Argo Biopharma is headquartered

Location

Headquarters

HQ city
Shanghai
HQ country
China
HQ region
Asia

Offices2 records

Markets served

Argo Biopharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Licensing and Milestone Payments: Argo Biopharma generates revenue through licensing deals with pharmaceutical companies. The company receives upfront payments, milestone payments tied to clinical and regulatory achievements, and tiered royalties on commercial sales.
  2. Strategic Collaborations: Multi-program RNAi licenses and strategic collaborations with Novartis generating upfront payments of $185 million in January 2024 and $160 million in September 2025, with total potential deal values exceeding $4 billion and $5 billion respectively.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Argo Biopharma product offering

Product offering

Core offering

Argo Biopharma is a clinical-stage biotechnology company that develops next-generation siRNA (small interfering RNA) therapeutics using its proprietary RADS platform (RNA molecules with superior Activity, Durability, and Safety). The company advances a pipeline of RNAi drug candidates targeting cardiovascular diseases, rare diseases, viral infections (HBV), complement-mediated diseases, and metabolic conditions, and monetizes these candidates through licensing and strategic collaboration agreements with global pharmaceutical companies such as Novartis.

Product overview

Argo Biopharma is a clinical-stage biotechnology company developing next-generation siRNA (small interfering RNA) therapeutics powered by its proprietary RADS platform. The company has a robust pipeline of multiple siRNA drug candidates targeting cardiovascular diseases (BW-01, BW-20829), rare diseases (BW-20805 for HAE), viral infections (BW-20507 for HBV), complement-mediated diseases (BW-40202 for PNH/IgAN), metabolic conditions, and specialty diseases. The company collaborates strategically with Novartis for several cardiovascular programs (BW-00163, BW-20829) and advances multiple candidates independently. Currently, seven RNAi candidates are in clinical development.

Differentiator

Problem solved

Functional benefit

Products and services

  • RADS siRNA Platform Proprietary siRNA drug discovery and development platform (RNA molecules with superior Activity, Durability, and Safety) used by Argo Biopharma to design, modify, and deliver next-generation RNAi therapeutics targeting a broad range of indications including cardiovascular diseases, rare diseases, viral infections, metabolic conditions, and CNS disorders. The platform supports sequence design, chemical modification, hepatic and extrahepatic delivery, and is engineered for long-acting dosing profiles.
  • BW-01 SiRNA therapeutic candidate for severe hypertriglyceridemia and cardiovascular disease, developed from the RADS platform; the first independently developed siRNA drug by Argo Biopharma.
  • BW-20805 (PKK) SiRNA therapeutic targeting prekallikrein (PKK) for the prophylactic treatment of hereditary angioedema (HAE); demonstrated 99% reduction in time-normalized HAE attack rate with 83% of participants attack-free at 600mg Q24W dose and over 90% plasma PKK reduction across all treatment groups.
  • BW-20507 SiRNA molecule targeting HBV messenger RNA for the treatment of chronic hepatitis B (CHB); received Breakthrough Therapy Designation from China CDE of NMPA based on potent antiviral activity and favorable safety profile in early-stage clinical trials.
  • BW-40202 (CFB) SiRNA therapeutic targeting complement factor B (CFB) mRNA in the liver for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN).
  • BW-50218 SiRNA therapeutic targeting transthyretin protein (TTR) for the potential treatment of ATTR amyloidosis and other TTR-related diseases, developed from the RADS platform with hepatic delivery.
  • BW-20829 (DII235) SiRNA therapeutic targeting elevated Lipoprotein(a) in patients with atherosclerotic cardiovascular disease; licensed to Novartis and progressed to Phase 2b under the exclusive collaboration agreement.
  • BW-00163 (QCZ484) SiRNA therapeutic for hypertension developed from the RADS platform; part of the exclusive license and collaboration agreement with Novartis (the fourth RADS platform asset to enter mid-stage clinical development).

Quantifiable outcome

  • BW-20805 achieved 99% reduction in time-normalized HAE attack rate with 83% of participants attack-free at 600mg Q24W dose
  • +4 more outcomes

Companies that use Argo Biopharma

Customer profile

Segments5 records

Ideal customer profiles3 records

Argo Biopharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Argo Biopharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship.

  • NovartisflagshipStrategic or Co-development Partner · 3 September 2025Expanded multi-asset collaboration with Novartis for cardiovascular disease programs. Novartis received option to license ex-China rights to two discovery-stage molecules for severe hypertriglyceridemia and mixed dyslipidemia, plus right of first negotiation for BW-00112 (ANGPTL3) in Phase II. Deal includes $160 million upfront, potential milestones up to $5.2 billion, and tiered royalties. This builds on the January 2024 partnership valued at $4.165 billion total potential.
  • NovartisflagshipStrategic or Co-development Partner · 7 January 2024Landmark multi-program RNAi licensing and strategic collaboration with Novartis. Argo granted Novartis exclusive global license for Phase 1 cardiovascular program, exclusive ex-Greater China license for Phase 1/2a cardiovascular program, and option to license compounds directed against up to two additional cardiovascular targets. Novartis paid $185 million upfront with total potential deal value up to $4.165 billion plus tiered royalties.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Argo Biopharma competitors and assessment

Company assessment

Direct peers

  • Alnylam Pharmaceuticals: Market-leading siRNA therapeutics company with multiple approved products (Givlaari, Oxlumo, Leqvio, Amvuttra). Directly comparable to Argo as a clinical/commercial-stage siRNA developer targeting similar cardiovascular, rare disease, and metabolic indications with GalNAc-conjugated RNAi platform.
  • Arrowhead Pharmaceuticals: Clinical-stage siRNA company with the TRiM platform targeting liver and extrahepatic tissues. Several Argo founders (CEO Dongxu Shu, CSO Patrick Shao) were previously at Arrowhead, making it the most direct platform and people-comparable peer.
  • Silence Therapeutics: UK-based clinical-stage siRNA company developing GalNAc-conjugated RNAi therapeutics for cardiovascular and rare diseases. Direct platform and indication overlap, including Lp(a) and cardiovascular programs that compete with Argo's BW-20829 and BW-00163.
  • Dicerna Pharmaceuticals (Novo Nordisk): Acquired by Novo Nordisk in 2021 for its GalXC RNAi platform. Direct platform peer historically; under Novo Nordisk, continues to compete in cardiometabolic RNAi — relevant comparable for what a major-pharma-acquired siRNA platform looks like at scale.

Broad incumbents

  • Ionis Pharmaceuticals: Established antisense oligonucleotide (ASO) therapeutics company with multiple approved products (Spinraza, Tegsedi, Waylivra). Competes in adjacent RNA-targeting modality for similar indications including cardiovascular and rare disease; relevant for platform validation and partnering models.
  • Novo Nordisk: Global pharmaceutical leader with significant RNAi investment through Dicerna acquisition and independent cardiovascular/metabolic programs. Comparable as the type of deep-pocketed incumbent that could be a future acquirer or strategic partner for Argo-style siRNA platforms.

Emerging players

  • Wave Life Sciences: Clinical-stage RNA therapeutics company using PRISM platform for stereopure oligonucleotides. Comparable as a smaller-cap RNA platform targeting neurological and rare diseases with differentiated chemistry — relevant peer for Argo's extrahepatic delivery ambitions.
  • Vir Biotechnology: Clinical-stage infectious disease company with siRNA-based hepatitis B program (VIR-2218). Directly comparable to Argo's BW-20507 for chronic hepatitis B as the leading competing RNAi approach to functional cure.

Others

  • Novartis: Argo's flagship strategic partner with multiple licensed siRNA programs and >$9B in potential deal value. Relevant as the incumbent that has validated Argo's platform and that any future investor would benchmark against for ongoing partnership economics.

Regional players

  • Ribocure Pharmaceuticals: China-based clinical-stage siRNA therapeutics company developing cardiovascular and rare disease RNAi drugs. Closest geographic/direct competitor in the China siRNA ecosystem, with overlapping cardiovascular and HAE programs.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Argo Biopharma social profiles

Digital presence

Argo Biopharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Argo Biopharma leadership team

Management profile

Number of profiles

Profiles5 records

Argo Biopharma funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Argo Biopharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Argo Biopharma

What does Argo Biopharma do?

Argo Biopharma is a clinical-stage biotechnology company that develops next-generation siRNA (small interfering RNA) therapeutics using its proprietary RADS platform (RNA molecules with superior Activity, Durability, and Safety). The company advances a pipeline of RNAi drug candidates targeting cardiovascular diseases, rare diseases, viral infections (HBV), complement-mediated diseases, and metabolic conditions, and monetizes these candidates through licensing and strategic collaboration agreements with global pharmaceutical companies such as Novartis.

Is Argo Biopharma a public or private company?

Argo Biopharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Argo Biopharma founded?

Argo Biopharma was founded in 2021. It employs 11 to 50 people.

Where is Argo Biopharma based?

Argo Biopharma is headquartered in Shanghai, China, in the Asia region.

How does Argo Biopharma make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are strategic Collaborations.

Who are Argo Biopharma's main competitors?

Direct peers on record are Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, Silence Therapeutics and Dicerna Pharmaceuticals (Novo Nordisk). Broad incumbents are Ionis Pharmaceuticals and Novo Nordisk. Emerging players are Wave Life Sciences and Vir Biotechnology. Novartis is listed as an others. Ribocure Pharmaceuticals is listed as a regional player.

Does Argo Biopharma have an API?

No public API is recorded for Argo Biopharma.

What industry is Argo Biopharma in?

Argo Biopharma's product category is RNAi Therapeutics / siRNA Drug Development. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MorningstarArgo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at Bradykinin Symposium 2026Argo Biopharma will present updated Phase II data for its siRNA therapeutic BW-20805 at the Bradykinin Symposium 2026 in Berlin. The data show mean monthly HAE attack rates decreased by 83-96% across dosing groups, with attack-free rates of 50-75% over 169 days. The company cites sustained PKK suppression and a well-tolerated safety profile.PR NewswireArgo Biopharma Doses First Participant in Phase I Clinical Trial of Factor XI Targeting siRNA Therapy BW-41012Argo Biopharma announced the first participant has been dosed in its Phase I study of BW-41012, an siRNA therapy targeting factor XI for thromboembolic diseases. The company also received NMPA IND approval for the drug this month. The study will assess safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers in Australia.pharmaphorumTrends & Insights: March 2026 – A pharmaphorum industry reportPharmaphorum's March 2026 industry report covers multiple developments across immuno-oncology, advanced therapies, dermatology, AI in healthcare, and manufacturing, highlighting shifts toward earlier intervention, regulatory acceleration, real-world evidence, and AI deployment at scale. Key active events include NVIDIA's $2 billion AI partnership with Nebius, Roche increasing investment in AI chips, Corcept Therapeutics securing FDA clearance for relacorilant in ovarian cancer, Argo Biopharma receiving FDA Fast Track Designation, and Brainomix deploying its AI stroke platform across all 25 WVU Health System sites. The report identifies governance maturity, operational readiness, and manufacturing capability as emerging constraints on innovation scalability, with the competitive landscape increasingly rewarding companies that invest in delivery infrastructure and regulatory foresight.PR NewswireArgo Biopharma to Present Positive Phase II Updated Results of siRNA Therapeutic BW-20805 for HAE at the EAACI 2026 CongressArgo Biopharma has been selected to present updated Phase II results for its siRNA therapeutic BW-20805 at the EAACI 2026 Congress in Istanbul, Türkiye, scheduled for June 12-15, 2026. The results demonstrate remarkable efficacy, with the 600mg Q24W dose achieving a 99% reduction in time-normalized HAE attack rate and 83% of participants remaining attack-free, while plasma prekallikrein declined by over 90% across all treatment groups. The drug was well tolerated across all three dosing regimens with no drug-related severe adverse events, supporting further evaluation of a long-acting Q6M dosing regimen for hereditary angioedema.Clinical Trials ArenaArgo Biopharma begins dosing for Phase I BW-50218 trialArgo Biopharma dosed the first subject in its Phase I trial of BW-50218, an siRNA targeting transthyretin, in Australia. The double-blind, placebo-controlled trial assesses tolerability, safety, and pharmacokinetics, with a milestone payment following. The company has seven RNAi candidates in clinical development.PR NewswireArgo Biopharma Announces First Subject Dosed in Phase I Study of siRNA Therapeutic BW-50218Argo Biopharma announced that the first subject has been dosed in its Phase I clinical trial evaluating BW-50218, an siRNA therapeutic targeting transthyretin protein, with the trial conducted in Australia. The company will receive a milestone payment for this advancement and highlighted its ongoing collaboration with Novartis to accelerate development of therapies for unmet medical needs. This dosing milestone represents the seventh molecule from Argo Biopharma's siRNA platform to enter clinical testing.PR NewswireArgo Biopharma Named to Fast Company's Annual List of the World's Most Innovative Companies of 2026Argo Biopharma, a clinical-stage siRNA therapeutics company headquartered in Shanghai and New York, has been named to Fast Company's World's Most Innovative Companies of 2026 list, joining notable companies such as Google, Nvidia, and Walmart. The company's pipeline includes BW-20507 for HBV which received Breakthrough Therapy Designation in China and entered Phase II, BW-20805 for HAE which received Fast Track Designation from the U.S. FDA, and an expanded 2025 collaboration with Novartis with multiple programs advancing to late-stage clinical development. Argo Biopharma currently has seven RNAi candidates in clinical development targeting cardiovascular diseases, viral infections, metabolic conditions, and specialty/rare diseases.PR NewswireArgo Biopharma Receives FDA Fast Track Designation for BW-20805, an Investigational siRNA Therapy for the Treatment of HAEArgo Biopharmaceutical Co., Ltd. has received FDA Fast Track Designation for BW-20805, its investigational siRNA therapy targeting prekallikrein for the treatment of hereditary angioedema. The company is currently conducting a global Phase II study in adult HAE patients with primary completion anticipated in the second half of 2026, followed by plans for a Phase III study. This designation enables more frequent FDA communication and eligibility for Priority Review and rolling NDA review.PR NewswireArgo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy OfficerArgo Biopharmaceutical Co., Ltd. announced the appointment of Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer, effective March 1, 2026. Dr. Wang brings nearly 20 years of biopharma capital markets and equity research experience, most recently serving as Managing Director and senior biotechnology analyst at Barclays. She is expected to leverage her expertise in RNA therapies and relationships within the financial community to help advance Argo Biopharma's pipeline of siRNA candidates through its next phase of growth.